Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October -- Here's Why

By Brian Feroldi – Nov 8, 2016 at 5:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two disappointing updates caused shares to tumble.

Image source: Getty Images.

What happened

Investors in Regeneron Pharmaceuticals (REGN 2.44%) had a rough October. Shares of the biotech giant fell 14.3% during the month, according to data from S&P Global Market Intelligence

REGN Chart

REGN data by YCharts.

So what

Two negative news releases appear to be responsible for the decline. 

First, Regeneron and its partner Teva Pharmaceuticals (TEVA -0.47%) announced that the FDA placed a clinical hold on a phase 2b study of fasinumab. This compound is a nerve growth factor antibody that is being researched as a potential treatment for osteoarthritis pain and chronic low back pain. The study showed that patients who used the higher doses of fasinumab developed arthropathy, an advanced joint disease. As a result, the FDA has requested that the study's protocol be changed.  

Second, Regeneron and Sanofi (SNY 1.70%) announced that the FDA had rejected their submission for sarilumab for treatment of rheumatoid arthritis. The agency stated that it could not approve the drug because of manufacturing issues that were identified in one of Sanofi's plants in France. 

Given the setbacks, it is easy to understand why shares dropped by double digits during the month -- especially given the sector-wide downturn.

Now what

Regeneron and its partners have already announced steps that they will take to rectify both situations.

In regard to fasinumab, Regeneron and Teva stated that future studies will exclude any patients who have advanced osteoarthritis and will only administer lower doses of the drug. As a result, both companies still believe that a pathway to regulatory approval still exists.

As to sarilumab, Sanofi has already submitted a comprehensive corrective action plan to the FDA and is already working on fixing its manufacturing issues. While Regeneron's management team wasn't yet able to provide an updated timeline, it did confirm that these manufacturing issues will not impact the approval decision, expected in March, of Dupixent, an atopic dermatitis drug. 

Overall, it wasn't a great month for shareholders, but since both issues appear to be fixable, I think that the long-term bull case for Regeneron is still intact. That's especially true in light of recent news that sales of cholesterol-lowering medicine Praluent are starting to pick up, which is an encouraging sign given the drug's slow start. That positions the company well to post strong growth into 2017 and beyond, so I for one plan on hanging on to my shares.  

Brian Feroldi owns shares of Regeneron Pharmaceuticals. The Motley Fool recommends Teva Pharmaceutical Industries. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.